Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.

Kusha A MohammadiTaylor BrackinGregory G SchwartzPhilippe Gabriel StegMichael S SzarekGaren ManvelianRobert PordySergio FazioGregory P Geba

Published in: Cancer medicine (2023)

Intensive low-density lipoprotein cholesterol lowering with a proprotein convertase subtilisin/kexin type 9 inhibitor combined with statin does not appear to increase the risk of new or worsening cancer events.

Keyphrases

low density lipoprotein
papillary thyroid
clinical trial
squamous cell
cardiovascular disease
coronary artery disease
type diabetes
childhood cancer